Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for its innovative oral diabetes medication, marking a significant advancement in the treatment of type 2 diabetes in China [1] Group 1: Product Information - The approved product is named Henggeli Jing Ruige Liting Metformin Sustained-Release Tablets (I) and (II) [1] - It is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] - The product is classified as a chemical drug of category 2.3, with specifications of 5/50/750 mg and 10/100/1000 mg [1] Group 2: Indications and Usage - The approved indication for the product is to improve blood sugar control in adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - It is categorized as a prescription drug [1]

Company Summary - Heng Rui Medicine has received approval from the National Medical Products Administration for its HR20031 tablet, which is the first self-developed oral hypoglycemic combination drug in China [1] - The HR20031 tablet combines three active ingredients: empagliflozin, regaglitazone, and metformin, aimed at improving blood sugar control in adults with type 2 diabetes who have inadequate control with metformin alone [2] - The total R&D investment for the HR20031 project has reached approximately 189.24 million yuan [2] Industry Summary - Diabetes has become the third most serious chronic disease affecting human health, following cancer and cardiovascular diseases [2] - According to the International Diabetes Federation, the diabetes prevalence rate among Chinese adults (ages 20-79) is 13.79%, with approximately 148 million patients, making China the country with the highest number of diabetes patients [2] - The clinical medication adherence for type 2 diabetes patients is poor, with only 50.1% achieving adequate blood sugar control [2] - The HR20031 tablet aims to simplify the treatment regimen by reducing the number of medications needed, thereby improving patient adherence [2] - Currently, there are no similar combination drugs approved for sale in China, while a comparable product, TRIJARDY XR, is available internationally [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年10月24日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 海外監管公告 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-165 江苏恒瑞医药股份有限公司 关于获得药品注册批准的公告 本公告乃根 ...

Major Events - Minglue Technology (02718) plans to offer 7.219 million Class A shares globally from October 23 to October 28, with cornerstone subscriptions amounting to $59 million [1] - Wisco Properties (00230) received a privatization offer from Wisco Hong Kong at a premium of approximately 104.08%, with trading resuming on October 24 [1] - Junyu Foundation (01757) was acquired by China Venture Capital Holdings for 75% of its shares at a discount of about 79.06%, with trading resuming on October 24 [1] - Kangda Foods (00834) was acquired by Gaosi Shi for approximately 54.69% of the company’s shares at a premium of about 16.23%, with trading resuming on October 24 [1] - Hutchison China MediTech (00013) presented data on HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targeted and Cancer Therapeutics [1] - Giant Bio (02367) received a medical device registration certificate for its Type I α1 collagen lyophilized fiber product [1] - Yiming Anke-B (01541) completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 combined with IMM01 [1] - Heng Rui Medicine (01276) received approval to conduct clinical trials for injection of Rikan Trastuzumab [1] - Hansoh Pharmaceutical (03692) had its application for HS-10365 capsule marketing approval accepted by the National Medical Products Administration [1] - Baixin An-B (02185) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [1] - Haotian International Construction Investment (01341) purchased a total of 646 units of Ethereum as of October 23 [1] Share Buybacks/Reductions - Cornerstone Pharmaceuticals-B (02616) saw CEO Yang Jianxin and senior management purchase an additional 1 million shares [2] - Midea Group (00300) repurchased 1.3434 million A shares for approximately 99.998 million yuan on October 23 [2] - China Communications Construction (01800) repurchased 119.45 million A shares for approximately 10.5994 million yuan on October 23 [2] - Mengniu Dairy (02319) repurchased 700,000 shares for approximately 10.0692 million HKD on October 23 [2] - Lianlian Digital (02598) spent about 7.5555 million HKD to repurchase 967,000 shares on October 23 [2] - Lianyi Rong Technology-W (09959) repurchased 2.47 million shares for approximately 7.4137 million HKD on October 23 [2] - Heng Rui Medicine (01276) repurchased 97,500 A shares for approximately 6.2808 million yuan on October 23 [2] - Gushengtang (02273) repurchased 19,860 shares for approximately 5.8634 million HKD on October 23 [2] Operating Performance - Ping An Good Doctor (01833) reported total revenue of approximately 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and plans to continue expanding AI technology to enhance medical service efficiency and quality [2] - Sands China Ltd. (01928) reported a 7.5% year-on-year increase in net revenue to $1.9 billion for the third quarter [2] - Livzon Pharmaceutical (01513) announced a net profit attributable to shareholders of 1.754 billion yuan for the first three quarters, a year-on-year increase of 4.86% [2] - China Railway Construction (01186) signed new contracts totaling 1.518765 trillion yuan in the first three quarters, a year-on-year increase of 3.08% [2] - Prada (01913) reported net revenue of 4.07 billion euros for the first three quarters, a year-on-year increase of 9% [2] Additional Performance Metrics - Baio Family Interactive (02100) reported 10.2 million active accounts in the third quarter, a year-on-year increase of 37.8% [3] - Anton Oilfield Services (03337) secured new orders worth 1.273 billion yuan in the third quarter [3]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injectable SHRA1811, a drug targeting HER2-positive breast cancer [1][2]. Group 1: Clinical Trial Approval - The clinical trial application for injectable SHRA1811 was accepted on July 31, 2025, and meets the requirements for drug registration, allowing the initiation of clinical trials [1]. - The trial will be a randomized, open-label, multi-center Phase III study comparing SHRA1811 with Docetaxel + Carboplatin + Trastuzumab + Pertuzumab for neoadjuvant treatment of early or locally advanced HER2-positive breast cancer [1]. Group 2: Product Mechanism and Market Context - Injectable SHRA1811 binds to HER2-expressing tumor cells, inducing apoptosis through the release of toxins in the lysosomes of tumor cells, which enhances anti-tumor efficacy [2]. - Similar products currently available in the market include Roche's Ado-trastuzumab emtansine and AstraZeneca's Fam-trastuzumab deruxtecan, both of which are already marketed in China [2]. - The global sales of similar products are projected to reach approximately $6.557 billion in 2024, with a cumulative R&D investment of about 141.475 million yuan for injectable SHRA1811 [2].

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injectable Rikan Trastuzumab, marking a significant step in the development of new cancer therapies [1][2]. Group 1: Clinical Trial Approval - The clinical trial application for injectable Rikan Trastuzumab (SHR-A1811) was approved, allowing for a Phase III study comparing it to a combination of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for the treatment of early or locally advanced HER2-positive breast cancer [1][2]. - The approval was based on compliance with the requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1]. Group 2: Product Mechanism and Market Context - Injectable Rikan Trastuzumab works by binding to HER2-expressing tumor cells, inducing apoptosis through the release of toxins within the cells [2]. - Similar products already on the market include Roche's Ado-trastuzumab emtansine and AstraZeneca's Fam-trastuzumab deruxtecan, both of which have been approved in China [2]. - The global sales of similar products are projected to reach approximately $6.557 billion in 2024, indicating a robust market for HER2-targeted therapies [2]. - The cumulative R&D investment for injectable Rikan Trastuzumab has reached approximately 141.475 million yuan [2].

Core Viewpoint - Heng Rui Medicine (01276.HK) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of injection Rituximab, which will commence soon [1] Group 1: Product Development - The injection Rituximab is set to be launched in China by May 2025 [1] - It is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 中國上海 2025年10月23日 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 一、药品的基本情况 药品名称：注射用瑞康曲妥珠单抗 剂 型：注射剂 证 ...

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月20日 | | 6,364,288,664 | | 14,713,610 | | | 6,379,002,274 | | 1). 購回股份 (股份被持作庫存股份) | | | -97,500 | 0.0015 % | 97 ...

Core Insights - The article highlights the current AH premium rates of various stocks, with Northeast Electric (00042), Sinopec Oilfield Service (01033), and Andeli Juice (02218) leading the premium rankings at 864.29%, 271.60%, and 243.99% respectively [1][2] - Conversely, CATL (03750), Hengrui Medicine (01276), and China Merchants Bank (03968) have the lowest AH premium rates, with values of -15.84%, 1.21%, and 1.28% respectively [1][2] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): H-share at 0.280 HKD, A-share at 2.25 CNY, premium rate of 864.29%, deviation value of 45.78% [1] - Sinopec Oilfield Service (01033): H-share at 0.810 HKD, A-share at 2.51 CNY, premium rate of 271.60%, deviation value of 47.60% [1] - Andeli Juice (02218): H-share at 16.050 HKD, A-share at 46.09 CNY, premium rate of 243.99%, deviation value of 14.60% [1] - The bottom three stocks with the lowest AH premium rates are: - CATL (03750): H-share at 535.000 HKD, A-share at 375.88 CNY, premium rate of -15.84%, deviation value of -0.86% [1] - Hengrui Medicine (01276): H-share at 76.300 HKD, A-share at 64.47 CNY, premium rate of 1.21%, deviation value of 4.33% [1] - China Merchants Bank (03968): H-share at 49.960 HKD, A-share at 42.24 CNY, premium rate of 1.28%, deviation value of -2.95% [1] Deviation Value Rankings - The stocks with the highest deviation values are: - Sinopec Oilfield Service (01033): premium rate of 271.60%, deviation value of 47.60% [1] - Northeast Electric (00042): premium rate of 864.29%, deviation value of 45.78% [1] - Shandong Molong (00568): premium rate of 122.86%, deviation value of 44.45% [1] - The stocks with the lowest deviation values are: - Tianjin Chuangye Environmental Protection (01065): premium rate of 60.04%, deviation value of -27.29% [2] - Shanghai Electric (02727): premium rate of 141.91%, deviation value of -21.13% [2] - China National Foreign Trade Transportation Group (00598): premium rate of 38.03%, deviation value of -17.35% [2]